Filing Flows › Vanda Pharmaceuticals (VNDA) › How it makes money
How Vanda Pharmaceuticals (VNDA) makes money
Vanda Pharmaceuticals (VNDA) made $69.8M of revenue in the third quarter 2026 (Q3 2026), +24% from a year earlier. Fanapt® brought in $38.8M (56%); HETLIOZ® net product sales brought in $21.7M (31%); PONVORY® net product sales brought in $7.7M (11%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Fanapt® | $38.8M | 55.5% | +8% | +24% |
| HETLIOZ® net product sales | $21.7M | 31.1% | +289% | +21% |
| PONVORY® net product sales | $7.7M | 11.1% | -2% | +10% |
| NEREUSTM | $1.6M | 2.3% | +57% | — |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $69.8M | 100.0% |
| Income tax | $174K | 0.2% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $69.8M | +24% |
| Q2 2026 | $50.5M | -4% |
| Q1 2026 | $51.7M | +3% |
| Q4 2025 | $57.2M | +8% |
| Q3 2025 | $56.3M | +18% |
| Q2 2025 | $52.6M | +4% |
| Q1 2025 | $50.0M | +5% |
From Vanda Pharmaceuticals' 10-Q filed Oct 29, 2026 (on EDGAR).
Questions
How does Vanda Pharmaceuticals make money?
Vanda Pharmaceuticals (VNDA) made $69.8M of revenue in the third quarter 2026 (Q3 2026), +24% from a year earlier. Fanapt® brought in $38.8M (56%); HETLIOZ® net product sales brought in $21.7M (31%); PONVORY® net product sales brought in $7.7M (11%).
What is Vanda Pharmaceuticals' biggest business?
Fanapt®: $38.8M in the third quarter 2026, 56% of revenue, +24% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.